Latest Conference Articles

Revumenib Displays Activity in Relapsed/Refractory KMT2A+ Acute Leukemias

Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.

Smoking May Increase Genetic Mutations, Disease Progression in MDS

Findings showed the potential impact of smoking on disease progression and survival in patients with myelodysplastic syndrome.

Blinatumomab Plus Chemo Increases DFS Rates in Standard-Risk Pediatric B-ALL

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.

Bicistronic CD19/CD22-Directed CAR T-Cell Therapy Is Safe, Elicits Durable Responses in Pediatric R/R B-ALL

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

Drs Baljevic and Cortes Preview Upcoming Studies and Emerging Data From ASH 2024

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

Dr Kumthekar on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal Disease

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Larotrectinib Induces Rapid, Durable Responses in Pediatric Patients With TRK Fusion+ CNS Tumors

Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.

Dr Gershon on Deep Responses With Mirdametinib in NF1-PN

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Dr Hansford on HRQOL Outcomes With Tovorafenib in Pediatric BRAF-Altered Low-Grade Glioma

Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.

Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma

Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.

Tovorafenib Leads to Durable Off-Treatment Responses in Pediatric BRAF-Altered R/R Low-Grade Glioma

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

Dr Reidy-Lagunes on the Evolving NET Treatment Paradigm

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.

Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

Roy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More

Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.

Transposon-Based BAFF CAR T Cells Show Early Efficacy, Safety in R/R Non-Hodgkin Lymphoma

Piecing Together the Proper BTK Usage in CLL

Nicole Lamanna, MD, highlights various clinical trials underway evaluating new treatment options for patients with chronic lymphocytic leukemia.

Real-World Experience With CAR T Varies From Trials in DLBCL

When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for consideration in these patient populations.

BTK Inhibitors, CAR T-Cell Therapy Drive Paradigm Changes in Follicular Lymphoma

Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.